The discovery of adult CMS stem cells and the development of mouse models have provided strong support for the transformation of CNS stem/precursor cells to gliomas by a series of genetic lesions. One of these changes is hyper-activation of the epidermal growth factor receptor (EGFR). The EGFR gene can be amplified and in addition, gliomas can express mutated EGFR's. The most common of these mutations is EGFRvlll, which has a constitutively activated kinase that activates PI3K, JNK and ERKs. Another glioma- associated change is loss of the tumor suppressor PTEN, which encodes a phosphatidylinositol phosphate phosphatase that opposes PI3K signaling. These clinical observations lead to the overall goal of this proposal. We will analyze how EGFRvlll expression and loss of PTEN alter cell signaling and tumorigenicity. These studies will take advantage of PTEN transgenic mouse models and EGFRvlll-bearing retroviruses. We will use precursor cells from the subventricular zone (SVZ) for these studies since we have extensive knowledge and experience with these cells, and they may be the origin of gliomas. Our preliminary data show that precursor cells with both EGFR expression and PTEN loss form tumors in nude mice. Furthermore, two cultures prepared from these tumors (tumor-conditioned) are karyotypic clones with enhanced tumor-forming potency and decreased capacity to differentiate. Our model is that EGFRvlll expression and PTEN loss transform the precursor cells, and the resulting chromosomal instability allows selection of aggressive, karyotypic clones.
Aim 1 is to determine whether PTEN acts as a suppressor or feedback loop of EGFRvlll signaling. Such a feedback loop might retard tumor progression caused by increased receptor tyrosine kinase signaling (e.g., EGFRvlll).
Aim 2 is examine the mechanism by which EGFRvlll expression and PTEN loss leads to centrosome amplification as well as chromosomal instability.
Aim 3 is to characterize tumor-conditioned cultures and determine whether there is a consistent pattern in which conditioned cells are more potent for tumor formation. These experiments will provide a basic understanding of how these genetic lesions interact and synergize to form tumors. These experiments will provide a basis for future development of new therapies and drugs to prevent tumor progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS021716-24
Application #
7575721
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Fountain, Jane W
Project Start
1988-03-01
Project End
2010-07-31
Budget Start
2009-01-01
Budget End
2010-07-31
Support Year
24
Fiscal Year
2009
Total Cost
$355,022
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Pharmacology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Weatherbee, Jessica L; Kraus, Jean-Louis; Ross, Alonzo H (2016) ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis. Oncotarget 7:43820-43834
Heinrich, Frank; Chakravarthy, Srinivas; Nanda, Hirsh et al. (2015) The PTEN Tumor Suppressor Forms Homodimers in Solution. Structure 23:1952-1957
Harishchandra, Rakesh K; Neumann, Brittany M; Gericke, Arne et al. (2015) Biophysical methods for the characterization of PTEN/lipid bilayer interactions. Methods 77-78:125-35
Ramirez, Yulian P; Mladek, Ann C; Phillips, Roger M et al. (2015) Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther 14:111-9
Karpel-Massler, Georg; Shu, Chang; Chau, Lily et al. (2015) Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget 6:14507-21
Pareja, Fresia; Macleod, David; Shu, Chang et al. (2014) PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res 12:987-1001
Jiang, Zhiping; Redfern, Roberta E; Isler, Yasmin et al. (2014) Cholesterol stabilizes fluid phosphoinositide domains. Chem Phys Lipids 182:52-61
Ramirez, Yulian P; Weatherbee, Jessica L; Wheelhouse, Richard T et al. (2013) Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 6:1475-506
Gericke, Arne; Leslie, Nicholas R; Lösche, Mathias et al. (2013) PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism. Adv Exp Med Biol 991:85-104
Shenoy, Siddharth; Shekhar, Prabhanshu; Heinrich, Frank et al. (2012) Membrane association of the PTEN tumor suppressor: molecular details of the protein-membrane complex from SPR binding studies and neutron reflection. PLoS One 7:e32591

Showing the most recent 10 out of 64 publications